Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Diluted Average): 2009-2015

Historic Shares Outstanding (Diluted Average) for Anika Therapeutics (ANIK) over the last 6 years, with Dec 2015 value amounting to $15.4 million.

  • Anika Therapeutics' Shares Outstanding (Diluted Average) fell 2.37% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2.37%. This contributed to the annual value of $15.4 million for FY2015, which is 0.49% up from last year.
  • Per Anika Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $15.4 million for FY2015, which was up 0.49% from $15.3 million recorded in FY2014.
  • In the past 5 years, Anika Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $15.4 million in FY2015 and a low of $13.7 million during FY2011.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $15.3 million (2014), whereas its average is $15.2 million.
  • Data for Anika Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 3.05% (in 2014) over the last 5 years.
  • Yearly analysis of 4 years shows Anika Therapeutics' Shares Outstanding (Diluted Average) stood at $13.7 million in 2011, then reached $14.8 million in 2013, then increased by 3.05% to $15.3 million in 2014, then rose by 0.49% to $15.4 million in 2015.